Fungi Bioactive Metabolites

Dr. Sunil Kumar Deshmukh is Scientific Advisor to Greenvention Biotech, Uruli-Kanchan, Pune, India, and Agpharm Bioinnovations LLP, Patiala, Punjab, India. Veteran industrial mycologist spent a substantial part of his career in drug discovery at Hoechst Marion Roussel Limited (now Sanofi India Ltd.), Mumbai, and Piramal Enterprises Limited, Mumbai. He has also served TERI-Deaken Nano Biotechnology Centre, TERI, New Delhi, and as an adjunct associate professor at Deakin University, Australia. He has to his credit 8 patents, 150 publications, and 20 books on various aspects of fungi and natural products of microbial origin. He is a president of the Association of Fungal Biologists (AFB) and a past president of the Mycological Society of India (MSI). He is a fellow of Mycological Society of India, the Association of Biotechnology and Pharmacy, the Society for Applied Biotechnology, and Maharashtra Academy of Science. Dr. Deshmukh serves as a referee for more than 20 national andinternational journals. He has approximately four decades of research experience in getting bioactive from fungi and keratinophilic fungi.Dr. Jacqueline Aparecida Takahashi is a full professor at the Universidade Federal de Minas Gerais (Brazil). For more than two decades, she has been studying routes to modulate fungal secondary metabolism, and she has been dedicated in recent years to issues related to access to Brazilian biodiversity, in reference to international treaties. She is a member of the Disciplinary Nucleus of Bioactive Natural Products of the Montevideo Group Universities Association (AUGM). She has to her credit 8 patents, 183 publications, and 12 book chapters on natural products from plants and fungi. She is a member of the Brazilian Society of Chemistry (SBQ) and of the Brazilian Society for the Progress of Science (SBPS). She serves as a referee for more than 20 national and international journals.Dr. Sanjai Saxena currently an academic and researcher with over two decades of experience in bio-tech research and development He is currently a full professor in the Department of Biotechnology, Thapar Institute of Engineering and Technology (Patiala), India. He has embarked upon his journey as an innovator turned entrepreneur and founded a startup, Agpharm Bioinnovations LLP with a pursuit to address the ever-arising unanswered pharmaceutical and agricultural sector needs. He continually focuses on exploring and exploiting novel biomolecules drawn from biological systems and their interactions in nature, particularly plant-microbe interactions.  Prof. Saxena, focuses his research primarily on microbial secondary metabolites, microbial diversity and bioprospecting, biochemistry, and drug discovery. His research work has resulted in significant extramural funding, 4 patents, over 78 peer-reviewed publications in referred research journals, 12 book chapters, and 1 book on applied microbiology to his credit. Dr. Saxena is a fellow of Association of Advancement of Biodiversity Science, Karnataka. Prof. Saxena serves as a referee for approximately 25 peer-reviewed journals apart from being on editorial board of a couple of them.

• Part I: Bioactive Compounds from Endophytic Fungi.- Chapter 1. Recent Advances in Pharmaceutically Important Compounds from Endophytic Fungi.-  Chapter 2. Pharmaceutically Important Compound Produced by Endophytic Fungi Having Anti-Infective Activity.- Chapter 3. Fungal Endophytes: An Accessible Natural Repository for Discovery of Bioactive Compounds.- Part II: Endolichenic Fungi: A Source of New Chemical Entities.- Chapter 4. Endolichenic Fungi as a Source of Pharmaceutically Active Compounds.- Chapter 5. Endolichenic Fungi, an Emerging Source of Bioactive Compounds: A Pharmaceutical Perspective.- Part III:  Marine Fungi as a Source of Medicinal Compounds.- Chapter 6. Antibiofilm Metabolites from Sponge-derived Aspergillus, Penicillium, and Fusarium for the Antibiotic Pipeline.- Chapter 7. Marine Fungi as a Bioresource of Medicinal Entities.- Chapter 8. Natural Bioactive Products from Marine Fungi against Bacterial Infection. Part IV: Fungi as a Bioresource of Pharmacologically Active Agents.- Chapter 9. Penicillium: A Treasure-Trove for Antimycobacterial and Antioxidant Metabolites.- Chapter 10. Metabolites from Fungi: a Promising Source of Lead Compounds against Cancer.- Chapter 11. Edible Mushrooms Substances as Natural Prevention in Autoimmunological Diseases.- Chapter 12. New Antifungal Drugs: Discovery and Therapeutic Potential.- Chapter 13. Fungal Enzyme Inhibitors: Potent Repository of Lead Compounds to Curb Cancer.- Chapter 14. Bioactive Metabolites from Fungi with Anti-Inflammatory and Anti-Thrombotic Properties; Current Status and Future Perspectives for Drug Development.- Chapter 15. Progress in the Development of Fungal Metabolites as New Drugs for Human Mycoses.- Part V: Fungi from Extremophilic Environment/Unique Ecosystems.- Chapter 16. Uncovering the Desert Fungal Enigma: An Attractive Resource for Biopharmaceuticals.- Chapter 17. Bioactive Metabolites Produced by Fungi Present inAntarctic, Arctic and Alpine Ecosystems.- Part VI: Novel Strategies to Screen or Enhance Secondary Metabolite Production.- Chapter 18. Enhancing Chemical Diversity of Fungal Secondary Metabolite by OSMAC Strategy.- Chapter 19. Epigenetic Regulation of Fungal Secondary Metabolites for the Enhancement of Therapeutically Active Compounds.- Chapter 20. Strategies for Enhancing the Production of Echinocandin.- Part VII:  Other by Products of Fungal Metabolism with Medicinal Applications.- Chapter 21. Fungal Pigments: Applications and Their Medicinal Potential.- Chapter 22. A Brief Insight into Peptide and Non-Peptide Drugs of Fungal Origin.- Chapter 23. Kojic Acid from Aspergillus wentii: A Journey from Isolation to Application.- Part VIII: Bioinformatics and Fungal Biotransformations in Pharmaceutical Drug Development.- Chapter 24. How Does Bioinformatics Play a Role in Fungal Drug Discovery?.- Chapter 25. Fungal Biotransformation of Steroids: History, Current Status, and Future Prospects.